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Purpose: Chronic pelvic pain syndrome (CPPS) is treated by use of various protocols. We compared tamsulosin monotherapy 
with tamsulosin in combination with antibiotics or anti-inflammatory agents and evaluated the efficacy of these treatments in 
patients with CPPS.
Methods: Patients (n=107) who were younger than 55 years and diagnosed with CPPS were randomly assigned to treatment 
with tamsulosin at 0.2 mg (group A), tamsulosin at 0.2 mg plus anti-inflammatory drugs (group B) or tamsulosin at 0.2 mg plus 
antibiotics (group C) daily. We applied the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) and 
the International Prostate Symptom Score (IPSS) to evaluate 100 patients who were treated for 12 weeks (7 withdrew). Scores of 
the three groups were compared by analysis of variance and we also evaluated subscores, which included pain, voiding and qual-
ity of life (QoL).
Results: All three groups showed statistically significant decreases in NIH-CPSI score, IPSS and subscore scores (P<0.05). There 
were no statistically significant differences between the groups except for the QoL domain of the IPSS (group A vs. C; P<0.01).
Conclusions: Tamsulosin monotherapy for 12 weeks was effective for treating patients with CPPS, compared with combination 
therapy with antibiotics or anti-inflammatory drugs. 
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INTRODUCTION
Prostatitis is a common disease with a lifetime prevalence rang-
ing from 5 to 16%. In Korea, about 25% of patients who visit a 
urology department for the treatment of genitourinary com-
plaints exhibit this disease [1,2]. It decreases the quality of life 
(QoL) for patients as much as unstable angina and active Crohn’s 
disease [3]. In 1968, Meares and Stamey published a landmark 
paper describing the differential diagnosis of prostatitis. Since 
then, many diagnostic tools and treatments have been investi-
gated [4]. However, patients and clinicians still feel frustrated 
when the treatment of prostatitis fails because its etiology is un-
clear [5]. Only 10% of patients are diagnosed with bacterial pros-
tatitis [6]. The other 90% of patients also have symptoms of 
prostatitis, including pelvic pain and urinary dysfunction. How-
ever, they are classified as having chronic nonbacterial prostati-
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tis/chronic pelvic pain syndrome (CP/CPPS), National Insti-
tutes of Health (NIH) category III, because of an absence of 
leukocytes or bacteria in the prostatic fluid [5].
  The symptoms of CP/CPPS are similar to those of benign 
prostatic hyperplasia (BPH) and investigators have hypothe-
sized that drugs effective for BPH might help some patients with 
CP/CPPS. Several studies have demonstrated that α-blockers 
improve the symptoms of CP/CPPS although the mechanisms 
by which the pain was relieved were unclear.
  Some studies have demonstrated no better effects than com-
bined therapy during 8 weeks.
  We conducted a prospective, randomized study to assess the 
efficacy of tamsulosin α-blocker monotherapy for CP/CPPS 
compared with combined therapy including antibiotics or anti-
inflammatory drugs for 12 weeks. We evaluated outcomes by 
using the NIH-Chronic Prostatitis Symptom Index (NIH-CP-
SI) score and the International Prostate Symptom Score (IPSS).
MATERIALS AND METHODS 
The study had a randomized, multicenter, parallel, prospective 
design. It was conducted at six hospitals in Busan, Korea. Patients 
aged younger than 55 years who were diagnosed with CP/CPPS 
were screened and then asked to participate in a prospective 
prostatitis treatment study running from March 1, 2008 to Feb-
ruary 28, 2009. Physical examinations, standard microbiologi-
cal cultures and microscopic analysis of urine, transrectal ultra-
sonography (TRUS) and serum prostate-specific antigen (PSA) 
measurements were used for the diagnosis of CP/CPPS. Patients 
were included if they had pain or discomfort in the pelvic region 
for at least 3 months, a total score of at least 12 on the NIH-CP-
SI and anticipated improvement of symptoms with therapy. 
Based on the number of leukocytes in the expressed prostatic 
secretions or post-prostatic massage voided urine, the patients 
were categorized as having NIH category IIIA (leukocyte count 
>10 high power field [HPF]) and IIIB (leukocyte count <10 
HPF). Patients with a urinary tract infection determined by urine 
study, hypoechoic lesions on TRUS, a serum PSA level of 3 ng/
dL or more or a history of disease that could have affected the 
results of this study were excluded. Finally, 107 patients who 
agreed to participate were randomly assigned to three groups. 
All patients were treated with tamsulosin 0.2 mg once daily. 
Group A received tamsulosin alone. Group B also received di-
clofenac 50 mg twice daily, and group C also received ciproflox-
acin 500 mg twice daily. We did not have placebo group, be-
cause the effects of each drugs such as a-blocker, antibiotics and 
non-steroidal anti-inflammatory drugs were widely known to 
the standard drug for CP/CPPS treatment. All patients under-
went 2 weeks of washout time from the first visit. Patients were 
enrolled to subgroup by the table of random sampling digit in 
each medical center. Patients were subjected to urine flow and 
residual urine volume measurements and completed question-
naires on the NIH-CPSI and the IPSS immediately after the 
washout time. In screening visit, seven patients dropped out, so 
the NIH-CPSI and IPSS were readministered to 100 patients 
who were treated for 12 weeks. We compared the baseline scores 
with post-treatment scores to analyze the efficacy of each treat-
ment. Differences between pre- and post-treatment scores of 
the three groups were compared by using analysis of variance 
(ANOVA). Subjective subscore including pain, voiding and QoL 
were also recorded. We used SPSS ver. 12 (SPSS Inc., Chicago, 
IL, USA) for the statistical analysis.
RESULTS 
Of the 107 patients who agreed to participate in this study, 7 
withdrew. Five patients were eliminated from the study because 
they had taken other anti-inflammatory drugs or antibiotics 
while the study was in progress. Two patients opted for trans-
urethral resection of the prostate. The three treatment groups 
were statistically similar in baseline characteristics (Table 1).
  Table 2 shows the difference between pre- and post-treatment 
scores. The baseline scores did not show statistically significant 
differences between the three groups. After 12 weeks of treat-
ment, the tamsulosin monotherapy group (group A) had a sig-
nificant reduction in mean NIH-CPSI total score (23.6±5.5 at 
baseline to 8.6±4.1 at week 12) and NIH-CPSI subscores (pain, 
voiding and QoL), as did groups B (23.9±5.9 to 7.7±4.9) and 
C (23.2±5.5 to 8.1±4.2) (both P<0.05; Table 2). The total scores 
Table 1. Comparison of baseline characteristics of patients
Characteristics Group A Group B Group C
No. of patients 40 32 28
Mean age (yr) 45.7 46.5 46.1
Mean prostate volume (cm
3) 30.1 29.7 29.4
Mean serum PSA level (ng/mL) 0.97 0.95 1.00
Mean maximal urine flow rate (mL/sec) 18.8 19.39 18.5
Mean residual urine volume (mL) 21.6 23.8 23.3
PSA, prostate-specific antigen.94    www.einj.or.kr
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and the three subscores of the IPSS (voiding, storage and QoL) 
also decreased in all three groups (group A, 14.3±6.2 to 7.2±3.8; 
 group B, 13.3±6.6 to 5.9±3.4; group C, 12.4±5.4 to 6.1±3.6)
(all P<0.05; Table 3). The data of the three groups showed suf-
ficient effects of treatment for patients with CP/CPPS. There 
were no statistically significant differences between groups 
shown by ANOVA, except for the QoL subscore of the IPSS 
(group A vs. C; P<0.01; Table 4).
DISCUSSION 
The etiology of CP/CPPS is unknown but can include microor-
ganisms, viruses, autoimmune disease, cytokines or reflux of 
urine to the prostate [7]. Many treatments have been investigat-
ed in pilot studies. These have included antibiotics, α-blockers, 
nonsteroidal anti-inflammatory agents, pentosan sulfate, allo-
purinol, quercetin, finasteride, weekly ejaculation, transurethral 
and subtotal prostatic resection, transurethral incision of the 
prostate, balloon dilatation, hyperthermia, transurethral needle 
ablation and radical prostatectomy [4]. The latest fashion for 
treating patients with CP/CPPS is the combination therapy of 
agents termed the “three As” antibiotics, nonsteroidal anti-in-
flammatory drugs and α1-blockers [8]. Since Osborn et al. [9] 
reported that the symptoms of CPPS were improved in 48% of 
patients by treatment with phenoxybenzamine, the α-blockers 
have attracted attention as drugs of choice for patients with CP/
CPPS. These drugs relieve lower urinary tract symptoms in pa-
tients with CP/CPPS because the α1-adrenergic blockade leads 
Table 2. Comparison of baseline scores with post-treatment scores (NIH-CPSI)
Group
NIH-CPSI
P-value Baseline Three months later
Total Pain
 a) Voiding
 a) QoL
 a) Total Pain
 a) Voiding
 a) QoL
 a)
A 23.6±5.5 11.4±3.9 4.2±2.0 8.1±2.3 8.6±4.1 4.0±3.2 1.6±1.5 3±1.98 <0.05
B 23.9±5.9 11.6±3.5 4.0±2.1 7.9±2.6 7.7±4.9 3.4±2.7 1.5±1.2 2.81±1.75 <0.05
C 23.17±5.5 10.9±4.0 3.7±1.5 8.5±2.1 8.1±4.2 3.7±2.8 1.7±1.0 2.8±1.5 <0.05
NIH-CPSI, National Institutes of Health-Chronic Prostatitis Symptom Index; QoL, quality of life.
a)Subscore.
Table 3. Comparison of baseline scores with post-treatment scores (IPSS)
Group
IPSS
P-value Baseline Three months later
Total Voiding
 a) Storage
 a) QoL
 a) Total Voiding
 a) Storage
 a) QoL
 a)
A 14.3±6.21 4.9±3.1 9.4±3.8 4.0±0.7 7.2±3.8 2.7±2.0 4.5±2.4 2.1±0.6 <0.05
B 13.3±6.6 4.9±3.8 8.4±4.3 4.0±0.9 5.9±3.4 2.1±1.7 3.8±2.3 1.9±0.7 <0.05
C 12.4±5.4 3.7±2.8 8.7±3.3 3.8±0.7 6.1±3.6 1.8±1.5 4.3±2.5 1.7±0.6 <0.05
IPSS, International Prostate Symptom Score; QoL, quality of life.
a)Subscore.
Table 4. Comparative analysis of each group by analysis of variance (ANOVA)
NIH-CPIS at 3 months IPSS at 3 months
Total Pain
 a) Voiding
 a) QoL
 a) Total Voiding
 a) Storage
 a) QoL
 a)
Group A vs. B 0.77 0.80 0.96 0.96 0.35 0.46 0.56 0.35
Group A vs. C 0.95 0.97 0.99 0.91 0.59 0.12 1.00 0.01
Group B vs. C 0.97 0.97 0.84 0.99 1.00 1.00 1.00 0.63
NIH-CPSI, National Institutes of Health-Chronic Prostatitis Symptom Index; International Prostate Symptom Score; QoL, quality of life.
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to smooth muscle relaxation in the bladder neck and prostate. 
This in turn permits increased urine flow and decreased urinary 
retention. How these agents relieve the pain associated with CP/
CPPS is less clear. It probably involves antagonizing local and 
spinal α1A and α1D receptors [10-12]. Cheah et al. [13] reported 
that 100 patients given 14 weeks of therapy with terazosine for 
CPPS had greater reductions in NIH-CPSI and IPSS scores than 
did a placebo group. Nickel et al. [14] reported that tamsulosin 
was superior to a placebo in providing symptomatic relief for 
patients with CP/CPPS, particularly among those with more 
severe symptoms. Mehik et al. [15] reported that 6 months of 
alfuzosin therapy for CP/CPPS resulted in a statistically signifi-
cant improvement in the NIH-CPSI compared with placebo, 
particularly in the pain domain, but the beneficial effect was 
only apparent only after several months of treatment and disap-
peared when treatment was discontinued. Here we evaluated 
the efficacy of tamsulosin, one of the “three As” drugs, for treat-
ing patients with CP/CPPS. We found that tamsulosin mono-
therapy was effective compared with combined therapy includ-
ing antibiotics or anti-inflammatory drugs. Therefore, we can 
consider adopting tamsulosin monotherapy for treating patients 
with CP/CPPS. However, many investigators still insist that CP/
CPPS is caused by pathogens, and other treatments including 
the use of muscle relaxants [16], anticholinergics, tricyclic anti-
depressants, finasteride [17], allopurinol [18], pentosan sulfate 
[19], phytotherapy [20], biofeedback [21], massage of the pros-
tate [22], and regular ejaculation [23] have been advocated. 
Furthermore, some urologists assume that patients with bacte-
rial prostatitis can be given a wrong diagnosis of nonbacterial 
prostatitis because cultures of their specimens are negative. This 
might arise because there are residual effects of previously taken 
antibiotics, individual differences in prostate massage skills for 
diagnosis, or prostatic duct obstruction caused by local inflam-
mation. Therefore, it has been suggested that the optimal treat-
ment plan for patients with CP/CPPS should be decided on 
only after evaluating the responses to antibiotics [22,24,25]. 
Nickel et al. [26] reported that 12 weeks of treatment with 
ofloxacin improved the symptoms in 50% of patients with CP/
CPPS. A study by Youn et al. [27] compared antibiotic mono-
therapy with a combination therapy of antibiotics and an 
α-blocker. They observed sufficient efficacy with both treat-
ments. Also, there have been many reports analyzing the effica-
cy of anti-inflammatory agents, for example refecoxib, a COX-2 
inhibitor, by Nickel et al. [28] and Ibuprofen by Minnery and 
Getzenberg [29] Thus, tamsulosin monotherapy may not be 
sufficient to treat patients with CP/CPPS because the etiology 
of this disorder has not been revealed. Therefore further study 
about the etiology of CP/CPPS and the action mechanism of 
alpha blockers such as tamsulosin is necessary.
  In conclusion, compared with combined therapies with anti-
biotics or anti-inflammatory drugs, tamsulosin monotherapy 
for 12 weeks was not inferior effects for treating patients with 
CP/CPPS. Tamsulosin monotherapy can be considered to treat-
ing CP/CPPS. Combination therapy with “three As” drug com-
binations and others are needed to maximize the effectiveness 
of treatment for CP/CPPS because there are some doubts about 
the etiology of this disorder. Therefore, we need further studies 
that adjust the methods of treatment to the clinical characteris-
tics of individual patients.
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